Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 6/20 | 0.51 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1412188 | 1.00 | EPHX1 (0.51) | EPHX1BTKKDM1AMAOBEPHX2 | |
| SCHEMBL1412190 | 1.00 | EPHX1 (0.51) | EPHX1BTKKDM1AMAOBEPHX2 | |
| SCHEMBL133307 | 0.92 | BTK (0.50) | EPHX1BTKKDM1AMAOBEPHX2 | |
| SCHEMBL183834 | 0.92 | BTK (0.50) | EPHX1BTKKDM1AMAOBEPHX2 | |
| SCHEMBL48274 | 0.92 | BTK (0.50) | EPHX1BTKKDM1AMAOBEPHX2 | |
| SCHEMBL25306007 | 0.92 | BTK (0.50) | EPHX1BTKKDM1AMAOBEPHX2 | |
| SCHEMBL25306009 | 0.92 | BTK (0.50) | EPHX1BTKKDM1AMAOBEPHX2 | |
| Hydrochloric Acid SCHEMBL31088698 | 0.91 | BTK (0.49) | EPHX1BTKKDM1AMAOBEPHX2 | |
| Hydrochloric Acid SCHEMBL30563288 | 0.91 | BTK (0.49) | EPHX1BTKKDM1AMAOBEPHX2 | |
| Hydrochloric Acid SCHEMBL27995727 | 0.91 | BTK (0.49) | EPHX1BTKKDM1AMAOBEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188100-B2 | Adenosine derivatives as A2A receptor agonists | NOVARTIS AG (CH) | 2012-05-29 | — | — | US | disclosed |
| US-8188100-B2 | Adenosine derivatives as A2A receptor agonists | NOVARTIS AG (CH) | 2012-05-29 | — | — | US | disclosed |
| US-20090325967-A1 | ADENOSINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
| US-20090325967-A1 | ADENOSINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325967-A1 | ADENOSINE DERIVATIVES AS A2A RECEPTOR AGONISTS | ADORA2A, ADORA2B, ADORA1 | EPHX1 1870/4885BTK 4580/4885KDM1A 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.